Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Swift Biosciences Announces $7 Million Series B Financing

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
Funds will support development of next gen sequencing and molecular diagnostic products.

Swift Biosciences, Inc. have announced the recent completion of a $7 million Series B financing led by Fletcher Spaght Ventures.  Also joining in the B round of investment was Renaissance Venture Capital Fund and the Series A investors, including the Mercury Fund, Michigan Accelerator Fund and several Michigan-based individual investors.

Swift Biosciences is a fast‐moving company focused on developing innovative, enabling

technologies for genomics and personalized medicine.  In February 2013, Swift entered the rapidly growing Next Generation Sequencing (NGS) space with its Accel-NGS™ line of sample preparation products. Swift’s myT® Primer technology provides both high sensitivity and specificity in mutation detection, making it ideal for cancer research and diagnostic applications.  myT Primer technology has been non-exclusively licensed to a global diagnostic company.

“This funding will support the expansion of our sales and marketing programs as well as accelerate new product introductions.  Our portfolio of creative, market-driven technologies continues to grow.” said David Olson, PhD, Chief Executive Officer of Swift Biosciences. 

Peter Kleinhenz, a Venture Partner with Fletcher Spaght Ventures, will be joining Swift's Board of Directors.  He commented that "We are excited about participating in the fastest growing life science market and partnering with such a talented team through our investment in Swift.  Their initial products and innovation pipeline offer compelling competitive advantages for next gen sequencing preparation, which is one of the bottlenecks in this field."  

Dr. Olson added “We are pleased to have new investors join our team and we also appreciate the continued support and enthusiasm of our existing investors.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Michigan Accelerator Fund I Invests $750,000 in Swift Biosciences
Innovative company develops enabling technologies for genomics and personalized medicine.
Friday, January 18, 2013
Scientific News
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!